key: cord-1009551-4o07a7jz authors: Nassar, Mahmoud; Daoud, Ahmed; Nso, Nso; Medina, Luis; Ghernautan, Victoria; Bhangoo, Harangad; Nyein, Andrew; Mohamed, Mahmoud; Alqassieh, Ahmed; Soliman, Karim; Alfishawy, Mostafa; Sachmechi, Issac; Misra, Anoop title: Diabetes mellitus and COVID-19: Review article date: 2021-09-04 journal: Diabetes Metab Syndr DOI: 10.1016/j.dsx.2021.102268 sha: fc20a847924f82c3bb3dc05aa27c0cba74fdcee8 doc_id: 1009551 cord_uid: 4o07a7jz BACKGROUND AND AIMS: We aim to cover most of the current evidence on the effect of both diabetes & COVID-19 infection on each other and the management of diabetic patients with COVID-19 infection. METHODS: We utilized databases to review the current evidence related to diabetes mellitus and COVID-19. RESULTS: We discussed the most recent evidence of diabetes milieus and COVID-19 regarding risk factors, management, complications, and telemedicine. CONCLUSIONS: Diabetes mellitus carry a significant risk of complications, more extended hospital stays, and mortality in COVID-19 infected patients. Diabetes mellitus is a well-known risk factor for worse clinical outcomes in patients with Coronavirus Disease 2019 . However, the relationship between these two entities seems to be bidirectional [1] . The ongoing pandemic of COVID-19 has significantly affected blood glucose control in patients with diabetes mellitus. The results of this can be classified into direct effects (those directly related to the viral infection) and indirect effects (those related to the impact of the pandemic on the management of blood glucose or the use of proposed treatments for the infection that also affect glucose homeostasis). As a direct effect, the COVID-19 infection has resulted in significant changes in patients' metabolism with significant elevations in blood glucose described as a consequence of the increased release of cytokines and inflammatory mediators, which lead to increased insulin resistance and associated hyperglycemia [2] . In addition, it has been suggested that COVID-19 might be involved in developing acute diabetes mellitus in certain patients by targeting ACE2 receptors located in pancreatic islets resulting in pancreatic injury [3] . Many therapies have been repurposed for the management of COVID-19. For instance, glucocorticoids have a remarkable impact on blood glucose. The use of this class of drugs has been associated with a decreased mortality in critically ill patients infected with COVID-19 [4] . It is well known that glucocorticoid use results in significant glucose homeostasis change due to increased gluconeogenesis and increased insulin resistance in various tissues [5] . Several studies have also described the indirect effects of the COVID-19 pandemic in diverse populations while undergoing lockdown. Some studies indicated that there J o u r n a l P r e -p r o o f is an improvement in glycemic control, while others state there is no significant change [6] or that there even is worsening of glycemic control in this population [7] . Herein we will review available literature related to Mellitus. Worsening hyperglycemia induces inflammation, endothelial dysfunction, and thrombosis via the generation of oxidative stress driving further dysregulation of glucose metabolism and hypercoagulability [9] . Severe infection in individuals predisposed to vasculopathy and impaired immunity may accentuate thrombotic and ischemic complications associated with multiorgan failure and increased mortality rates. All forms of DM can be characterized by abnormal signaling along pathways involved in glucose metabolism. DM is considered a vasculopathy equivalent as a progression of the disease is associated with both macrovascular and microvascular damage. Chronic hyperglycemia and insulin resistance contribute to vasculopathy through various mechanisms. These mechanisms include abnormal signaling along the AGE-RAGE and oxidative damage. Increased formation of advanced glycation end products (AGEs) and activation of the receptor for advanced glycation end products (RAGE) in the AGE-RAGE axis can accelerate vascular damage [10] . In addition, metabolic abnormalities associated with oxidative damage cause changes in mitochondrial expression of superoxide in endothelial cells of both large and small vessels. Over time, increased superoxide production mediates a cascade of epigenetic alterations that result in persistent expression of proinflammatory pathways even after normalization of blood glucose levels [11] . Alterations in innate and adaptive immunity, including abnormal cytokine responses, inhibition of leukocyte recruitment, and neutrophil dysfunction, are also driven by states of chronic hyperglycemia [12] . The complications of chronic hyperglycemia are compounded during acute viral infections as activated immune responses can promote systemic insulin resistance and worsening hyperglycemia [13] . In fact, severe COVID-19 progression is significantly associated with increased blood glucose level [14] . In the setting of concomitant SARS-CoV-2 infection and DM, monitoring blood glucose levels to track worsening hyperglycemia has more J o u r n a l P r e -p r o o f prognostic value than hemoglobin A1c (HgbA1c) in these patients. These findings suggest that worsening hyperglycemia occurs acutely and may drive rapid clinical deterioration in patients with pre-existing vasculopathy and endothelial dysfunction. While the relationship between Diabetes mellitus and COVID-19 remains complex, worsening glycemic control and aberrant immune responses may contribute to poor disease progression by accelerating thrombotic and ischemic complications associated with multiorgan failure and increased mortality rates. Type 2 Diabetes Mellitus (T2DM) is considered a risk factor for a worse prognosis in COVID-19 [1]. Many mechanisms have been described to explain the poorer prognosis of COVID-19 in diabetics, but these remain hypothetical at the time of this article . Some of these mechanisms include impaired neutrophil degranulation and complement activation, increased glucose concentration in airway secretion, which significantly increases viral replication, exaggerated proinflammatory cytokine response in diabetes, decreased viral clearance, and a more significant presence associated comorbidities [15] . An essential aspect of the relationship between COVID-19 and T2DM is that hyperglycemia at hospital admission is more relevant for prognostic purposes than the hemoglobin A1C. It is thought that COVID-19 predisposes infected individuals to hyperglycemia, leading to hyperglycosylation of the angiotensin-converting enzyme 2 (ACE2), the natural viral receptor at the host cell surface [16] . The acute hyperglycemia in these patients induces inflammation, endothelial dysfunction, and thrombosis via the generation of oxidative stress [2] . This may also enhance tissue tropism and viral penetration within the cells leading to increased virulence, pathogenicity, and susceptibility to more clinically severe infections. It has been hypothesized that the COVID-19 might affect pancreatic B-cells insulin production, which would worsen underlying glycemic control in the setting of T2DM [17] . Regardless of the mechanisms, when comparing covid-19 patients with and without T2DM, the patients with T2DM tend to develop more severe forms of the disease and tend to have a more significant increase in inflammatory markers compared to non-diabetics (i.e., higher levels of C-reactive protein, procalcitonin, ferritin, lactic dehydrogenase, and d-dimer) [18] . Furthermore, the prevalence of diabetes patients hospitalized in intensive care units for COVID-19 is two-to threefold higher, and the mortality rate at least doubles than that of non-diabetes patients [17] . There is limited evidence suggesting that newly diagnosed diabetes might be associated with a higher admission rate to ICU, invasive mechanical ventilation, and mortality risk than pre-existing diabetes [19] . Studies have also shown that a family history of T2DM might also represent a significant risk factor for this infection. Healthy individuals with a family history of T2DM tend to develop early endothelial dysfunction. Endothelial dysfunction has been reported to be a critical event in the pathophysiology of COVID-19, which has been associated with pulmonary microvascular thrombosis. Hyperinsulinemia and hyperglycemia seen in this population could favor the expression of ACE2 in various tissues, including microvascular endothelial cells known to act as a receptor for Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) [20] . Based on these findings, T2DM affects the disease severity and is one of the independent risk factors for inadequate therapeutic response in patients with COVID-19 [18] . Understanding the interactions between these two diseases is crucial in developing appropriate therapeutic approaches. Further studies are warranted to elucidate the mechanisms by which diabetes affects these patients' prognosis and how these pathways can be modified to generate better outcomes in this population. J o u r n a l P r e -p r o o f The prevalence of type 1 diabetes mellitus (T1DM) in COVID-19 patients range from 0.15% to 28.98% [21] . Hyperglycemia has been seen to be a risk factor for COVID-19-related complications. According to preliminary findings from a multicenter surveillance study in the United States that assessed clinical outcomes of COVID-19 in patients with T1DM, 48.5% of patients had high blood glucose levels; 45.5%, elevated temperature; 39.4%, dry cough; 33.3%, excess fatigue, and vomiting; 30.3%, shortness of breath; 27.3%, nausea; and 21.2%, body/headaches [22] . Additionally, abdominal and chest pain, chills, loose stools, and loss of taste and smell were reported by <15% of patients [22] . In these patients with COVID-19 and T1DM, obesity (39.4%) and hypertension or cardiovascular disease (12.1%) were the most prevalent comorbidities, while diabetic ketoacidosis was the most prevalent adverse outcome [22] . In a whole-population study that assessed the independent effects of diabetes status and type on in-hospital death in English patients with COVID-19, 1.5% of inhospital COVID-19-related deaths were seen to occur in patients with T1DM versus 31.4% in those with type 2 diabetes. [23] Over the study's 72-day period, unadjusted mortality rates per 100,000 individuals were 138 for those with T1DM versus 27 for those without diabetes. Interestingly, when adjusted for age, sex, deprivation, ethnicity, and geographical region, the odds ratio (OR) for in-hospital COVID-19related death was 3.51 (95% CI 3.16-3.90) in patients with T1DM [23] . A population-based cohort study assessed the associations between risk factors and mortality due to COVID-19 in patients with T1DM. [24] Older age and male sex were seen to be associated with increased COVID-19-related mortality. [24] COVID-19-related mortality was also significantly increased in those with black and Asian ethnicities. [ 53-3.56 , P<0.0001]) was seen to be associated with significantly increased COVID-19-related deaths. [24] Impaired renal function and previous hospital admissions with stroke or heart failure were also associated with significantly increased COVID-19-related mortality (P<0.0001). [24] A cross-sectional, web-based survey involved all Italian pediatric diabetes centers in determining if the diagnosis of pediatric T1DM or its acute complications were altered during the early phase of COVID-19. [25] Compared with 2019, a 23% reduction was observed in new diabetes cases in 2020. [25] Among newly diagnosed patients with diabetic ketoacidosis (DKA), the proportion of patients with severe DKA in 2020 was 44.3% compared to 36.1% in 2019 (P=0.03). [25] Hence, the COVID-19 pandemic might have changed the presentation of diabetes and the severity of DKA [25] . Herein we discuss both oral and injectable non-insulin antidiabetics[summarized in Table 1 ] as well as insulin and their relation to COVID-19 management and outcomes. It has been described a potential reduction in mortality with its use in patients with type 2 diabetes and covid-19 infection. Its use should be continued in patients with type 2 diabetes mellitus until hospitalized or unless contraindicated. It is unclear at this point whether its potential mortality benefit extends to inpatient use or in non-diabetic covid-19 patients. Possible reduction in inflammatory markers. There is no significant evidence to promote its use in patients with diabetes mellitus and covid-19 infection. Further studies are needed to elucidate its potential benefit. Potential reduction in disease severity. Studies have not demonstrated a significant difference in rate of ICU admissions or disease severity with its use. Several studies found no significant difference in rate mortality rate, poor prognosis, or rate of ICU admission. However, others did find some benefit in rate of intubation, severity of disease, and discharge rate. Further studies are needed to elucidate its potential benefit. Anti-inflammatory properties; decrease in lactic acidosis of dapagliflozin, which could potentially reverse acid-base balance in hypoxia. Studies have not demonstrated a significant difference in disease severity or mortality rates. Improvement in right ventricular function and anti-inflammatory effects during acute lung injury. There is limited data available. Some studies have shown no significant difference in rate of ICU admissions or mortality. Table 1 Antidiabetics and COVID-19 adapted from singh et al [26] . Most type 2 DM patients on oral hypoglycemics take Metformin, either alone or with other drugs. Metformin is the preferred initial drug to treat type 2 DM. Metformin therapy may be associated with lactic acidosis. This is rare in the absence of other factors predisposing to lactic acidosis but could happen in patients suffering renal impairment, severe infections, or sepsis. [27] Metformin can be continued in asymptomatic COVID-19 patients or patients with mild symptoms. However, Metformin should be stopped in patients hospitalized with severe COVID-19 infection due to the risk of lactic acidosis [28] . It is worth mentioning that better outcomes have been reported in COVID-19 patients receiving Metformin. [29] It is hypothesized that Metformin may inhibit virus entry into cells through adenosine monophosphate (AMP)-activated protein kinase activation and the B-mammalian target of rapamycin (m TOR) signaling pathway [30] . Sulfonylureas may induce hypoglycemia, so in patients with severe COVID-19 with inadequate oral intake, it is safer to stop them. In addition, simultaneous use of hydroxychloroquine may increase the risk of hypoglycemia [31] . DPP-4 inhibitors are well tolerated and can be continued safely in COVID-19 patients. [29] They are associated with a low risk of hypoglycemia. DPP-4 may act as a receptor for some coronaviruses. DPP-4 inhibitors might inhibit such binding and mitigate COVID-19 infection. [32] However, this hypothetical advantage has not been proven in clinical trials. [29] Glucagon-like peptide-1 receptor agonists (GLP-1 agonists) GLP-1 agonists may decrease water intake [15] . They may also cause nausea and vomiting. Thus, GLP-1 agonist therapy is associated with an increased risk of dehydration and aspiration pneumonia. Pioglitazone upregulates Angiotensin converting-2 enzyme (ACE-2) in rat tissues, [35] leading to concerns that it may increase COVID-19 severity since ACE2 acts as a receptor for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to enter cells [36] . [28] The DARE-19 trial is a recent study that aims to evaluate the role of sodium-glucose cotransporter 2 (SGLT-2) inhibitors in non-critically ill patients hospitalized due to covid-19 infection. The investigation is a double-blinded, placebo-controlled, phase III study centered on evaluating the impact of dapagliflozin on the incidence of complications and all-cause mortality in patients with respiratory failure infected with covid-19. Patients with and without diabetes were included in the study. Its primary endpoint was to assess organ failure or death in patients treated with this SGLT-2 inhibitor versus placebo. Secondary outcomes included the evaluation of composite kidney endpoint and all-cause mortality [41] . The patients were randomized to receive either dapagliflozin 10 mg daily or a placebo for 30 days. A total of 1,250 patients were enrolled and followed for a total of 90 days. Those who were critically ill at the time of presentation, with significantly impaired kidney function (GFR <25 ml/min/1.73m2), type 1 diabetes mellitus, or prior history of diabetic ketoacidosis were excluded. The study results have shown no significant reduction in organ dysfunction, death, or improvement in recovery in patients treated with dapagliflozin compared to placebo [42] . Insulin therapy is preferred for hospitalized patients, including moderate to severe Hyperglycemia is a well-known, established risk factor for mortality due to infections, mainly due to pneumonia. COVID-19 is characterized by pneumonia that has led to the death of over 1. 65 and acute kidney injury in 5% [51] . It is worth mentioning that acute kidney injury, whether associated with hyperglycemia or not, is a predictor of a bad outcome in COVID-19 patients. This meta-analysis confirms that hyperglycemia is a predisposing factor for the death and progression of non-critical diseases to critical diseases in patients with COVID-19, both in diabetes and diabetes [51] . Hyperglycemic complications of diabetes mellitus include Diabetic Ketoacidosis (DKA), hyperosmolar hyperglycemic syndrome (HHS). DKA is the commonest of these complications, with the highest hospitalizations rates that also increased in the last decade in developed countries, but fortunately, mortality decreased to less than 0.5% [52] . As with other severe infections, DKA can occur in diabetic patients with COVID-19. Severe Acute Respiratory Syndrome Coronavirus-1 (SARS-CoV-1) was found to bind to the ACE2 receptor in the pancreatic islets, which causes cellular damage J o u r n a l P r e -p r o o f leading to acute onset of diabetes DKA [53] ; hence COVID-19 was expected to have a similar mechanism. One study in Wuhan, China, reported the prevalence of ketonemia or ketonuria among hospitalized COVID-19 patients to be 6.4%, with 7% of them meeting American Diabetes Association (ADA) DKA criteria and all of them had a prior diagnosis of diabetes mellitus [54] . Many studies and case reports later reported new-onset diabetes with DKA as the presenting symptom in COVID-19 or DKA without respiratory symptoms, and even euglycemic DKA was reported [55] . COVID-19 has also been linked to new onset T1DM with DKA and pancreatic autoantibodies [56] . Data were presented from many countries with variable presentations, In a study done in Peru, 14 patients were admitted with DKA, and four of them were diagnosed with COVIDs-19, and two of them had associated findings suggestive of pancreatitis. [57] An Australian hospital's number of DKA diagnoses during the COVID-19 pandemic was increased but comparable, while the number of severe DKA was significantly higher (45% vs. 5%; P <0.003). [58] In the UK, it was noticed that diabetes mellitus was overrepresented in hospitalized COVID-19 patients (31%) while its national prevalence is 7% and data of T2DM hospital bed occupancy was 18% before the pandemic, with DKA present in 2% of hospitalized Steroids have been diabetes rivals for decades, although used in almost every specialty in medicine with many short-term and long-term treatment courses for their anti-inflammatory and immunosuppressive actions with subsequent undesirable side effects such as osteoporosis, hypertension, hyperglycemia, and steroid-induced diabetes [63] . Many factors contribute to the degree of hyperglycemia, including duration of treatment, dosage, relative potency, and associated infection. The higher the dose of steroid therapy, the higher the risk of developing steroid-induced diabetes. The use of steroids in diabetic patients increases the risk of hospitalization due to uncontrolled blood sugar [64] . In Following the warning, many institutions initiated observational studies and randomized controlled trials (RCT) on steroid therapy for COVID-19, with the most extensive study in the UK, also known as The RECOVERY trial, which showed dexamethasone as opposed to usual care reduced 28-day mortality in patients requiring oxygen therapy or mechanical ventilation [66] . Following this study and as of September 2, 2020, the WHO changed prior recommendations, and now steroids remain the only drug of proven benefit for Covid-19 patients. Steroids have beneficial effects in states of hyper inflammation, which is the hallmark of Covid-19 but at the expense of worsening hyperglycemia, new-onset diabetes, and hyperglycemic complications. DM is an important prognostic factor, as studies have shown a 10-fold higher risk of death in this patient population [67] . In addition, a disturbing glucolipid metabolism undoubtedly leads to immunosuppression by decreasing the innate immune response , and COVID 19 itself leads to a weakening of the immune system by lowering the T-lymphocyte count [68] . As a result, these patients are more susceptible to other bacterial, viral, and fungal infections. Candida species (Albicans and non-Albicans) are among the fungal co-infections observed in COVID-19 patients and present as invasive candidiasis. It can also cause fungal pneumonia. Another severe fungal superinfection is invasive pulmonary aspergillosis which is associated with high mortality rates. The diagnosis implies microbiological and/or histopathological evidence using special fungal staining [69] . Cryptococcal disease and pneumocystis jirovecii have also been detected in COVID-19 patients, particularly those treated with immunosuppressants [68] . J o u r n a l P r e -p r o o f It has been described a potential reduction in mortality with its use in patients with type 2 diabetes and covid-19 infection. Its use should be continued in patients with type 2 diabetes mellitus until hospitalized or unless contraindicated. It is unclear at this point whether its potential mortality benefit extends to inpatient use or in non-diabetic covid-19 patients. Possible reduction in inflammatory markers. There is no significant evidence to promote its use in patients with diabetes mellitus and covid-19 infection. Further studies are needed to elucidate its potential benefit. Potential reduction in disease severity. Studies have not demonstrated a significant difference in rate of ICU admissions or disease severity with its use. It has been proposed that DPP-4 could be involved with the receptor binding domain of SARS-CoV-2. Furthermore, it could offer antiinflammatory, anti-fibrotic and immunomodulatory effects. Several researchers have proposed its use as a repurposed agent for COVID-19. Several studies found no significant difference in rate mortality rate, poor prognosis, or rate of ICU admission. However, others did find some benefit in rate of intubation, severity of disease, and discharge rate. Further studies are needed to elucidate its potential benefit. Anti-inflammatory properties; decrease in lactic acidosis of dapagliflozin, which could potentially reverse acid-base balance in hypoxia. Studies have not demonstrated a significant difference in disease severity or mortality rates. Improvement in right ventricular function and anti-inflammatory effects during acute lung injury. There is limited data available. Some studies have shown no significant difference in rate of ICU admissions or mortality. Characteristics and outcomes of diabetic patients infected by the SARS-CoV-2. The Pan African medical journal Hyperglycemia and COVID-19: What was known and what is really new? Diabetes research and clinical practice COVID-19 vaccine-induced myocarditis case report with literature review Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis Dexamethasone in the era of COVID-19: friend or foe? An essay on the effects of dexamethasone and the potential risks of its inadvertent use in patients with diabetes Comparison of the effects of lockdown due to COVID-19 on glucose patterns among children, adolescents, and adults with type 1 diabetes: CGM study Short-term impact of COVID-19 lockdown on metabolic control of patients with well-controlled type 2 diabetes: a single-centre observational study COVID-19 and diabetes mellitus: from pathophysiology to clinical management Hyperglycemia and COVID-19: What was known and what is really new? Diabetes, Hypertension, and Cardiovascular Disease: Clinical Insights and Vascular Mechanisms Oxidative stress and diabetic complications Type 2 Diabetes and its Impact on the Immune System Virus-Induced Interferon-γ Causes Insulin Resistance in Skeletal Muscle and Derails Glycemic Control in Obesity The Impact of COVID-19 on Blood Glucose: A Systematic Review and Meta-Analysis. Front Endocrinol (Lausanne) COVID-19: the endocrine opportunity in a pandemic Response to: Is newly diagnosed diabetes a stronger risk factor than pre-existing diabetes for COVID-19 severity Prognostic factors in patients with diabetes hospitalized for COVID-19: Findings from the CORONADO study and other recent reports Impacts of Type 2 Diabetes on Disease Severity, Therapeutic Effect, and Mortality of Patients With COVID-19 Independent Impact of Diabetes on the Severity of Coronavirus Disease 2019 in 5,307 Patients in South Korea: A Nationwide Cohort Study Could a family history of type 2 diabetes be a risk factor to the endothelial damage in the patient with COVID-19? Medical hypotheses The association between COVID-19 and type 1 diabetes mellitus: A systematic review Type 1 Diabetes and COVID-19: Preliminary Findings From a Multicenter Surveillance Study in the U.S. Diabetes care Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study. The Lancet Diabetes & Endocrinology Has COVID-19 Delayed the Diagnosis and Worsened the Presentation of Type 1 Diabetes in Children? Diabetes Care Non-insulin anti-diabetic agents in patients with type 2 diabetes and COVID-19: A Critical Appraisal of Literature Metformin-associated lactic acidosis: Current perspectives on causes and risk Practical recommendations for the management of diabetes in patients with COVID-19. The Lancet Diabetes & Endocrinology Clinical Characteristics and Outcomes of Patients With Diabetes and COVID-19 in Association With Glucose-Lowering Medication. Diabetes Care Metformin in COVID-19: A possible role beyond diabetes. Diabetes research and clinical practice COVID-19 in people with diabetes: understanding the reasons for worse outcomes. The Lancet Diabetes & Endocrinology COVID-19 and diabetes: Can DPP4 inhibition play a role? Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials Glucagon-like peptide 1 receptor signaling attenuates respiratory syncytial virus-induced type 2 responses and immunopathology Glucagon-like peptide-1 (GLP-1) reduces mortality and improves lung function in a model of experimental obstructive lung disease in female mice Pioglitazone upregulates angiotensin converting enzyme 2 expression in insulinsensitive tissues in rats with high-fat diet-induced nonalcoholic steatohepatitis Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19 Pioglitazone inhibits the expression of inflammatory cytokines from both monocytes and lymphocytes in patients with impaired glucose tolerance Management of diabetes in patients with COVID-19 Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVID-19: Design and rationale for the DARE-19 study Dapagliflozin in Respiratory Failure in Patients With COVID-19 and diabetes mellitus: from pathophysiology to clinical management Intensive insulin therapy exerts antiinflammatory effects in critically ill patients and counteracts the adverse effect of low mannose-binding lectin levels Treating type 2 diabetes in COVID-19 patients: the potential benefits of injective therapies World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard Glycemic Characteristics and Clinical Outcomes of COVID-19 Patients Hospitalized in the United States Fasting blood glucose at admission is an independent predictor for 28-day mortality in patients with COVID-19 without previous diagnosis of diabetes: a multi-centre retrospective study Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes. Cell metabolism Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China Effects of hyperglycaemia on complications of COVID-19: A meta-analysis of observational studies Diabetic Ketoacidosis in COVID-19: Unique Concerns and Considerations Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes COVID-19 infection may cause ketosis and ketoacidosis Euglycemic diabetic ketoacidosis in a patient with type 1 diabetes and SARS-CoV-2 pneumonia: case report and review of the literature New-onset Type 1 Diabetes Mellitus with Diabetic Ketoacidosis and Pancreatitis in a Patient with COVID-19 Diabetic ketoacidosis during COVID-19 pandemic in a developing country Increased paediatric presentations of severe diabetic ketoacidosis in an Australian tertiary centre during the COVID-19 pandemic High prevalence of COVID-19-associated diabetic ketoacidosis in UK secondary care. Diabetes research and clinical practice Letter to the editor: Unexpected high mortality in COVID-19 and diabetic ketoacidosis A Pragmatic Approach to Inpatient Diabetes Management during the COVID-19 Pandemic Steroid-induced diabetes: a clinical and molecular approach to understanding and treatment Current systematic reviews and meta-analyses of COVID-19 Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19 Clinical Characteristics and Outcomes of Type 2 Diabetes Patients Infected with COVID-19: A Retrospective Study. Engineering (Beijing) High mortality co-infections of COVID-19 patients: mucormycosis and other fungal infections. Discoveries (Craiova) Fungal Co-infections Associated with Global COVID-19 Pandemic: A Clinical and Diagnostic Perspective from China Coccidioidomycosis and COVID-19 Co-Infection, United States, 2020. Emerg Infect Dis Influenza co-infection associated with severity and mortality in COVID-19 patients Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India Telemedicine for diabetes care in India during COVID19 pandemic and national lockdown period: Guidelines for physicians OCR announces notification of enforcement discretion for telehealth remote communications during the COVID-19 Nationwide Public Health Emergency Telemedicine can lower costs and improve access Funding: None. The authors confirm the absence of personal and financial interests impacting the outcomes of this research study.